Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Abstract Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of advanced pancreatic cancer following progress...

Full description

Bibliographic Details
Main Authors: Danielle C. Glassman, Randze L. Palmaira, Christina M. Covington, Avni M. Desai, Geoffrey Y. Ku, Jia Li, James J. Harding, Anna M. Varghese, Eileen M. O’Reilly, Kenneth H. Yu
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Nanoliposomal irinotecan
MM-398
Nal-IRI
5-fluorouracil
Online Access:http://link.springer.com/article/10.1186/s12885-018-4605-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4605-1

Similar Items